

Preliminary Final Report – Reporting Adjustments

Melbourne, Australia – Tryptamine Therapeutics Limited (**‘Tryp’** or the **‘Company’**) (**ASX: TYP**), a clinical-stage biotechnology company, advises that the Annual Report of Tryptamine Therapeutics Limited lodged concurrently on the ASX includes adjustments not included in Tryp’s Appendix 4E: Preliminary Final Report released on 30 August 2024 (Preliminary Final Report).

The adjustments relate to the following:

- The company had initial options and awards in place through to the transaction date, with these original awards not newly issued as at 1 May 2024. The options and awards were rolled over on completion of the reverse acquisition transaction. The initial accounting treatment assumed an expense through the P&L for the options and awards for \$4.025 million. The revised accounting treatment assumed the awards were modified and as a result, the arrangement does not result in an additional cost of the transaction. The initial share-based payment expense was reversed as a result with the impact being a decrease in share based payment expense by \$4.025 million.
- The company had initially recognised a warrants reserve of \$0.765 million on reverse acquisition transaction completion. The revised accounting treatment resulted in ‘retiring’ the warrants reserve, with a corresponding decrease in general expenses on the basis that no material warrant contracts were executed as part of the transaction and nothing disclosed within the Prospectus on warrants post transaction.
- Additional Research & Development expenditure claimable under the Research and Development Tax Incentive resulting in an increase to other revenue and other receivables by \$0.135 million.
- Recognition of additional accrued expenditure relating to various operating expenses including insurance and share registry costs, resulting in an increase in general expenses and accruals by \$0.122 million.

The adjustments are outlined in the table below:

		Preliminary Final Report \$	Change \$	FY24 Annual Report \$
Consolidated Statement of Financial Position	Total assets	7,317,305	135,447	7,083,307
	Total liabilities	(1,951,243)	118,631	(1,832,612)
	Net assets	5,366,062	254,078	5,620,140
	Accumulated losses	31,132,110	1,059,243	30,072,867
	Equity	5,366,062	254,078	5,620,140



Consolidated Statement of Profit or Loss and Other Comprehensive Income	Total revenue	985,057	131,345	1,116,402
	Finance costs	(699,305)	159,086	(540,219)
	Share based payments	(4,852,879)	3,365,633	(1,487,246)
	General and administration expenses	(1,208,304)	729,328	(478,976)
	Total expenses	(12,464,245)	5,205,273	(7,258,972)
	Loss after income tax	(11,479,188)	5,336,618	(6,412,570)
	Total comprehensive loss	(11,479,188)	5,336,618	(6,412,570)

This announcement has been authorised for release by the Board of Tryptamine Therapeutics Limited.

-ENDS-

About Tryptamine Therapeutics Limited

Tryp Therapeutics is a clinical-stage biotechnology company focused on developing proprietary, novel formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs. Tryp's lead program, TRP-8803, is a proprietary formulation of IV-infused psilocin (the active metabolite of psilocybin) with potential to alleviate numerous shortcomings of oral psilocybin including: significantly reducing the time to onset of the psychedelic state, controlling the depth and duration of the psychedelic experience, and reducing the overall duration of the intervention to a commercially feasible timeframe. The Company has completed a Phase 2a clinical trial for the treatment of binge eating disorder at the University of Florida, which demonstrated an average reduction in binge eating episodes of greater than 80%.

The Company also has also just completed a Phase 2a clinical trial for the treatment of fibromyalgia in collaboration with the University of Michigan and has initiated a Phase 2a clinical trial in collaboration with Massachusetts General Hospital for the treatment of abdominal pain and visceral tenderness in patients suffering from irritable bowel syndrome. Each of the studies is utilising TRP-8802 (synthetic, oral psilocybin) to demonstrate clinical benefit in these indications. Where a positive clinical response is demonstrated, subsequent studies are expected to utilise TRP-8803 (IV-infused psilocin), that has the potential to further improve efficacy, safety, and patient experience. TRP-8803 is currently being evaluated in a Phase 1 Healthy Volunteer Study in Adelaide, Australia.



For more information, please visit www.trypttherapeutics.com.

Investor & Media Contact

Jason Carroll
Chief Executive Officer
Tryptamine Therapeutics Limited
jcarroll@trypttherapeutics.com

Henry Jordan
Six Degrees Investor Relations
+61 (0) 431 271 538
henry.jordan@sdir.com.au

Forward-Looking Information

Certain information in this news release, constitutes forward looking information. In some cases, but not necessarily in all cases, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "targets", "expects" or "does not expect", "is expected", "an opportunity exists", "is positioned", "estimates", "intends", "assumes", "anticipates" or "does not anticipate" or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might", "will" or "will be taken", "occur" or "be achieved". In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts but instead represent management's expectations, estimates and projections regarding future events. Forward-looking information is necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by Tryp as of the date of this news release, are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward looking information, including but not limited to the factors described in greater detail in the "Risk Factors" section of Tryp's Replacement Prospectus available at www.asx.com.au. These factors are not intended to represent a complete list of the factors that could affect Tryp; however, these factors should be considered carefully. There can be no assurance that such estimates and assumptions will prove to be correct. The forward-looking statements contained in this news release are made as of the date of this news release, and Tryp expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.